Applegate et al. reported a dextran-based nanomedicine delivering PPARα/γ agonists to adipose tissue macrophages, resulting in weight loss, restored glucose tolerance, and WAT browning across multiple obesity models [131]. Here, PPARA is linked to obesity disorder.